Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study

Creators: Turner, Nicholas C; Balmaña, Judith; Poncet, Coralie; Goulioti, Theodora; Tryfonidis, Konstantinos; Honkoop, Aafke H; Zoppoli, Gabriele; Razis, Evangelia; Johannsson, Oskar T; Colleoni, Marco; Tutt, Andrew N; Audeh, William; Ignatiadis, Michail; Mailliez, Audrey; Trédan, Olivier; Musolino, Antonino; Vuylsteke, Peter; Juan-Fita, Maria Jose; Macpherson, Iain R J; Kaufman, Bella; Manso, Luis; Goldstein, Lori J; Ellard, Susan L; Láng, István; Jen, Kai Yu; Adam, Virginie; Litière, Saskia; Erban, John; Cameron, David A

Others:: Turner, Nicholas C; Balmaña, Judith; Poncet, Coralie; Goulioti, Theodora; Tryfonidis, Konstantino; Honkoop, Aafke H; Zoppoli, Gabriele; Razis, Evangelia; Johannsson, Oskar T; Colleoni, Marco; Tutt, Andrew N; Audeh, William; Ignatiadis, Michail; Mailliez, Audrey; Trédan, Olivier; Musolino, Antonino; Vuylsteke, Peter; Juan-Fita, Maria Jose; Macpherson, Iain R J; Kaufman, Bella; Manso, Lui; Goldstein, Lori J; Ellard, Susan L; Láng, István; Jen, Kai Yu; Adam, Virginie; Litière, Saskia; Erban, John; Cameron, David A

Description

To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer.